Bayer, Bristol-Myers Squibb and Ono Pharma enter into clinical collaboration agreement
Bayer, Bristol-Myers Squibb and Ono Pharma announced a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with MSS mCRC. July 18, 2019